Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis

• Published in: Arthritis research & therapy 2023-05, Vol.25 (1), p.80-80, Article 80
• Main Authors: Braun, Juergen, Blanco, Ricardo, Marzo-Ortega, Helena, Gensler, Lianne S, Van den Bosch, Filip, Hall, Stephen, Kameda, Hideto, Poddubnyy, Denis, van de Sande, Marleen, van der Heijde, Désirée, Zhuang, Tingting, Stefanska, Anna, Readie, Aimee, Richards, Hanno B, Deodhar, Atul
• Format: Article
• Language: English
• Subjects: Adult; Arthritis; Axial spondyloarthritis; Diagnosis; Diagnosis, Radioscopic; Drug therapy; Edema; Humans; Inflammation; Inflammation - pathology; Magnetic resonance imaging; Magnetic Resonance Imaging - methods; Methods; Monoclonal antibodies; Non-Radiographic Axial Spondyloarthritis; Nr-axSpA; Patient outcomes; Patients; Quality of life; Radiograph; Reading; Reading promotion; Sacroiliac Joint - diagnostic imaging; Sacroiliac Joint - pathology; Sacroiliitis; Sacroiliitis - pathology; Secukinumab; Spondylarthritis - diagnostic imaging; Spondylarthritis - drug therapy; Spondylarthritis - pathology; Spondylitis, Ankylosing - diagnostic imaging; Spondylitis, Ankylosing - drug therapy; Spondylitis, Ankylosing - pathology; Spondyloarthropathies; X-ray
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-023-03051-5

Radiographic progression and course of inflammation over 2 years in patients with non-radiographic axial spondyloarthritis (nr-axSpA) from the phase 3, randomized, PREVENT study are reported here. In the PREVENT study, adult patients fulfilling the Assessment of SpondyloArthritis International Society classification criteria for nr-axSpA with elevated CRP and/or MRI inflammation received secukinumab 150 mg or placebo. All patients received open-label secukinumab from week 52 onward. Sacroiliac (SI) joint and spinal radiographs were scored using the modified New York (mNY) grading (total sacroiliitis score; range, 0-8) and modified Stoke Ankylosing Spondylitis Spine Score (mSASSS; range, 0-72), respectively. SI joint bone marrow edema (BME) was assessed using the Berlin Active Inflammatory Lesions Scoring (0-24) and spinal MRI using the Berlin modification of the AS spine MRI (ASspiMRI) scoring (0-69). Overall, 78.9% (438/555) of patients completed week 104 of the study. Over 2 years, minimal changes were observed in total radiographic SI joint scores (mean [SD] change, - 0.04 [0.49] and 0.04 [0.36]) and mSASSS scores (0.04 [0.47] and 0.07 [0.36]) in the secukinumab and placebo-secukinumab groups. Most of the patients showed no structural progression (increase ≤ smallest detectable change) in SI joint score (87.7% and 85.6%) and mSASSS score (97.5% and 97.1%) in the secukinumab and placebo-secukinumab groups. Only 3.3% (n = 7) and 2.9% (n = 3) of patients in the secukinumab and placebo-secukinumab groups, respectively, who were mNY-negative at baseline were scored as mNY-positive at week 104. Overall, 1.7% and 3.4% of patients with no syndesmophytes at baseline in the secukinumab and placebo-secukinumab group, respectively, developed ≥ 1 new syndesmophyte over 2 years. Reduction in SI joint BME observed at week 16 with secukinumab (mean [SD], - 1.23 [2.81] vs - 0.37 [1.90] with placebo) was sustained through week 104 (- 1.73 [3.49]). Spinal inflammation on MRI was low at baseline (mean score, 0.82 and 1.07 in the secukinumab and placebo groups, respectively) and remained low (mean score, 0.56 at week 104). Structural damage was low at baseline and most patients showed no radiographic progression in SI joints and spine over 2 years in the secukinumab and placebo-secukinumab groups. Secukinumab reduced SI joint inflammation, which was sustained over 2 years. ClinicalTrials.gov, NCT02696031.